{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gallbladder+Neoplasms", "query": { "condition": "Gallbladder Neoplasms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 172, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gallbladder+Neoplasms&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T12:47:25.576Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01093222", "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Adenocarcinoma", "Gallbladder Adenocarcinoma", "Gallbladder Adenocarcinoma With Squamous Metaplasia", "Hilar Cholangiocarcinoma", "Recurrent Extrahepatic Bile Duct Carcinoma", "Recurrent Gallbladder Carcinoma", "Undifferentiated Gallbladder Carcinoma", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2010-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-06-30", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 141, "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marysville", "state": "California" }, { "city": "Novato", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093222" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" }, { "nct_id": "NCT02631590", "title": "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Carcinoma", "Gall Bladder Carcinoma", "Cholangiocarcinoma", "Gastrointestinal Tumor" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-07-05", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631590" }, { "nct_id": "NCT01135849", "title": "B-Receptor Signaling in Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinomas", "Amyloidosis", "Anal Cancer", "Anemia", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Transitional Cell Carcinoma of Bladder", "Bone Marrow Transplant Failure", "Bone Cancer", "Cancer of Brain and Nervous System", "Breast Cancer", "Carcinoma of the Large Intestine", "Endocrine Cancer", "Esophageal Cancer", "Eye Cancer", "Gall Bladder Cancer", "Gastric (Stomach) Cancer", "Gastrooesophageal Cancer", "Gastrointestinal Stromal Tumor (GIST)", "Gynecologic Cancers", "Head and Neck Cancers", "Hepatobiliary Neoplasm", "Kidney (Renal Cell) Cancer", "Leukemia", "Lung Cancer", "Hodgkin Disease", "Lymphoma, Non-Hodgkin", "Mesothelioma", "Multiple Myeloma", "Myelodysplastic Syndromes (MDS)", "Neuroendocrine Tumors", "Myeloproliferative Disorders", "Pancreatic Cancer", "Prostate Cancer", "Skin Cancer", "Soft Tissue Sarcoma", "Testicular Cancer", "Thymus Cancer", "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Daniel Bernstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 99, "start_date": "2008-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01135849" }, { "nct_id": "NCT00949949", "title": "Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma of the Gallbladder", "Localized Gallbladder Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-09", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949949" }, { "nct_id": "NCT00422877", "title": "Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer of the Liver" ], "interventions": [ { "name": "Taxoprexin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Regent, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-01", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00422877" }, { "nct_id": "NCT00588263", "title": "Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Lung Cancer", "Melanoma", "Non-Hodgkin's Lymphoma", "Uterine Cancer", "CORPUS UTERI,ENDOMETRIUM", "LUNG", "OVARY" ], "interventions": [], "intervention_types": [], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2000-07", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-02-19", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588263" }, { "nct_id": "NCT03257761", "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extrahepatic Bile Duct Adenocarcinoma, Biliary Type", "Gallbladder Adenocarcinoma, Biliary Type", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Cholangiocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Gallbladder Cancer AJCC V7", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage III Intrahepatic Cholangiocarcinoma AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7", "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7", "Unresectable Gallbladder Carcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-02-07", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 3, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257761" }, { "nct_id": "NCT02812186", "title": "Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cholecystitis", "Endometriosis", "Bowel Obstruction", "Fibroids", "Prostate Cancer", "Chronic Kidney Disease", "Uterine Prolapse" ], "interventions": [ { "name": "Deep to Moderate NMB", "type": "PROCEDURE" }, { "name": "Moderate to Deep NMB", "type": "PROCEDURE" }, { "name": "Rocuronium", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2016-12-27", "completion_date": "2019-02-06", "has_results": true, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02812186" }, { "nct_id": "NCT05712356", "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Gallbladder Cancer", "Gallbladder Carcinoma", "Intrahepatic Cholangiocarcinoma", "Extrahepatic Cholangiocarcinoma", "Bile Duct Cancer", "Gall Bladder Cancer", "Gall Bladder Carcinoma" ], "interventions": [ { "name": "certepetide", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-05-13", "completion_date": "2026-04-05", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T12:47:25.576Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712356" } ] }